A prospective clinicopathologic study of dose-modified CODOX-M/TVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)
- Author
- MEAD, Graham M1 ; BARRANS, Sharon L2 ; WENDI QIAN3 ; WALEWSKI, Jan4 ; RADFORD, John A5 ; WOLF, Max6 ; CLAWSON, Simon M3 ; STENNING, Sally P3 ; YULE, Claire L3 ; JACK, Andrew S2
[1] Southampton University Hospitals Trust, Southampton, United Kingdom
[2] Haematological Malignancy Diagnostic Service, Leeds General Infirmary, Leeds, United Kingdom
[3] MRC Clinical Trials Unit, London, United Kingdom
[4] MSCM Cancer Center, Warsaw, Poland
[5] Christie Hospital, Manchester, United Kingdom
[6] Peter MacCallum Cancer Centre, Melbourne, Australia
UK National Cancer Research Institute Lymphoma Clinical Studies Group and the Australasian Leukaemia and Lymphoma Group, United Kingdom - Source
Blood. 2008, Vol 112, Num 6, pp 2248-2260, 13 p ; ref : 54 ref
- ISSN
- 0006-4971
- Scientific domain
- Medical oncology; Hematology
- Publisher
- The Americain Society of Hematology, Washington, DC
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Cytogénétique Dose Essai clinique Histopathologie Homme Hématologie Immunophénotype Lymphome Burkitt Prospective Sporadique Hémopathie lymphoïde B Cancer Hémopathie maligne Infection Lymphome non hodgkinien Syndrome lymphoprolifératif Virose
- Keyword (en)
- Cytogenetics Dose Clinical trial Histopathology Human Hematology Immunophenotype Burkitt lymphoma Prospective Sporadic B cell neoplasm Cancer Malignant hemopathy Infection Non Hodgkin lymphoma Lymphoproliferative syndrome Viral disease
- Keyword (es)
- Citogenética Dosis Ensayo clínico Histopatología Hombre Hematología Inmunofenotipo Linfoma Burkitt Prospectiva Esporádico Cáncer Hemopatía maligna Infección Linfoma no Hodgkin Linfoproliferativo síndrome Virosis
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B05 Infectious diseases / 002B05C Viral diseases
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B19 Hematologic and hematopoietic diseases / 002B19B Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
- Discipline
- Blood diseases Infectious pathology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 20641114
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1182/blood-2008-03-145128 
https://dx.doi.org/10.1182/blood-2008-03-145128
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1182\/blood-2008-03-145128\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:188:\"A prospective clinicopathologic study of dose-modified CODOX-M\/TVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial)\";s:9:\"\u0000*\u0000jtitle\";s:5:\"Blood\";s:9:\"\u0000*\u0000stitle\";s:5:\"Blood\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:3:\"112\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"2248\";s:8:\"\u0000*\u0000epage\";s:4:\"2260\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0006-4971\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"MEAD\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Graham M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:17:\"BARRANS, Sharon L\";i:1;s:10:\"WENDI QIAN\";i:2;s:13:\"WALEWSKI, Jan\";i:3;s:15:\"RADFORD, John A\";i:4;s:9:\"WOLF, Max\";i:5;s:16:\"CLAWSON, Simon M\";i:6;s:17:\"STENNING, Sally P\";i:7;s:14:\"YULE, Claire L\";i:8;s:14:\"JACK, Andrew S\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:188:\"A prospective clinicopathologic study of dose-modified CODOX-M\/TVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial)\";s:8:\"\u0000*\u0000place\";s:14:\"Washington, DC\";s:6:\"\u0000*\u0000pub\";s:35:\"The Americain Society of Hematology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"13\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1182\/blood-2008-03-145128\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:188:\"A prospective clinicopathologic study of dose-modified CODOX-M\/TVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial)\";s:9:\"\u0000*\u0000jtitle\";s:5:\"Blood\";s:9:\"\u0000*\u0000stitle\";s:5:\"Blood\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:3:\"112\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"2248\";s:8:\"\u0000*\u0000epage\";s:4:\"2260\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0006-4971\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"MEAD\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Graham M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:17:\"BARRANS, Sharon L\";i:1;s:10:\"WENDI QIAN\";i:2;s:13:\"WALEWSKI, Jan\";i:3;s:15:\"RADFORD, John A\";i:4;s:9:\"WOLF, Max\";i:5;s:16:\"CLAWSON, Simon M\";i:6;s:17:\"STENNING, Sally P\";i:7;s:14:\"YULE, Claire L\";i:8;s:14:\"JACK, Andrew S\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:188:\"A prospective clinicopathologic study of dose-modified CODOX-M\/TVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial)\";s:8:\"\u0000*\u0000place\";s:14:\"Washington, DC\";s:6:\"\u0000*\u0000pub\";s:35:\"The Americain Society of Hematology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"13\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:28:\"10.1182\/blood-2008-03-145128\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1182\/blood-2008-03-145128\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:188:\"A prospective clinicopathologic study of dose-modified CODOX-M\/TVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial)\";s:9:\"\u0000*\u0000jtitle\";s:5:\"Blood\";s:9:\"\u0000*\u0000stitle\";s:5:\"Blood\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:3:\"112\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"2248\";s:8:\"\u0000*\u0000epage\";s:4:\"2260\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0006-4971\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"MEAD\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Graham M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:17:\"BARRANS, Sharon L\";i:1;s:10:\"WENDI QIAN\";i:2;s:13:\"WALEWSKI, Jan\";i:3;s:15:\"RADFORD, John A\";i:4;s:9:\"WOLF, Max\";i:5;s:16:\"CLAWSON, Simon M\";i:6;s:17:\"STENNING, Sally P\";i:7;s:14:\"YULE, Claire L\";i:8;s:14:\"JACK, Andrew S\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:188:\"A prospective clinicopathologic study of dose-modified CODOX-M\/TVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial)\";s:8:\"\u0000*\u0000place\";s:14:\"Washington, DC\";s:6:\"\u0000*\u0000pub\";s:35:\"The Americain Society of Hematology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"13\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1182\/blood-2008-03-145128\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:188:\"A prospective clinicopathologic study of dose-modified CODOX-M\/TVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial)\";s:9:\"\u0000*\u0000jtitle\";s:5:\"Blood\";s:9:\"\u0000*\u0000stitle\";s:5:\"Blood\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:3:\"112\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"2248\";s:8:\"\u0000*\u0000epage\";s:4:\"2260\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0006-4971\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"MEAD\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Graham M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:17:\"BARRANS, Sharon L\";i:1;s:10:\"WENDI QIAN\";i:2;s:13:\"WALEWSKI, Jan\";i:3;s:15:\"RADFORD, John A\";i:4;s:9:\"WOLF, Max\";i:5;s:16:\"CLAWSON, Simon M\";i:6;s:17:\"STENNING, Sally P\";i:7;s:14:\"YULE, Claire L\";i:8;s:14:\"JACK, Andrew S\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:188:\"A prospective clinicopathologic study of dose-modified CODOX-M\/TVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial)\";s:8:\"\u0000*\u0000place\";s:14:\"Washington, DC\";s:6:\"\u0000*\u0000pub\";s:35:\"The Americain Society of Hematology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"13\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1182\/blood-2008-03-145128\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:188:\"A prospective clinicopathologic study of dose-modified CODOX-M\/TVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial)\";s:9:\"\u0000*\u0000jtitle\";s:5:\"Blood\";s:9:\"\u0000*\u0000stitle\";s:5:\"Blood\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:3:\"112\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"2248\";s:8:\"\u0000*\u0000epage\";s:4:\"2260\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0006-4971\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"MEAD\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Graham M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:17:\"BARRANS, Sharon L\";i:1;s:10:\"WENDI QIAN\";i:2;s:13:\"WALEWSKI, Jan\";i:3;s:15:\"RADFORD, John A\";i:4;s:9:\"WOLF, Max\";i:5;s:16:\"CLAWSON, Simon M\";i:6;s:17:\"STENNING, Sally P\";i:7;s:14:\"YULE, Claire L\";i:8;s:14:\"JACK, Andrew S\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:188:\"A prospective clinicopathologic study of dose-modified CODOX-M\/TVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial)\";s:8:\"\u0000*\u0000place\";s:14:\"Washington, DC\";s:6:\"\u0000*\u0000pub\";s:35:\"The Americain Society of Hematology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"13\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
